Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
pozelimab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04811716 | Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy | Phase 2 Interventional | Regeneron Pharmaceuticals | ||
NCT04209634 | Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) | Phase 2/Phase 3 Interventional | Regeneron Pharmaceuticals | ||
NCT05070858 | A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis | Phase 3 Interventional | Regeneron Pharmaceuticals |